Sensitivity of human laryngeal squamous cell carcinoma Hep-2 to metrotexate chemoterapy
Aim: Methotrexate (MTX) is an antifolate agent that acts inhibiting purine and pyrimidine synthesis. The objective of the study was to evaluate the viability of Hep-2 human laryngeal cancer cells to the treatment with MTX chemotherapy in vitro. Methods: Cultured Hep-2 cells were treated with 0.25, 2...
Збережено в:
| Опубліковано в: : | Experimental Oncology |
|---|---|
| Дата: | 2012 |
| Автори: | , , , , |
| Формат: | Стаття |
| Мова: | Англійська |
| Опубліковано: |
Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
2012
|
| Теми: | |
| Онлайн доступ: | https://nasplib.isofts.kiev.ua/handle/123456789/139856 |
| Теги: |
Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|
| Назва журналу: | Digital Library of Periodicals of National Academy of Sciences of Ukraine |
| Цитувати: | Sensitivity of human laryngeal squamous cell carcinoma Hep-2 to metrotexate chemoterapy / A.L.S. Galbiatti, H.C. Caldas, J.A. Padovani Junior, E.C. Pavarino, E.M. Goloni-Bertollo // Experimental Oncology. — 2012. — Т. 34, № 4. — С. 367-369. — Бібліогр.: 22 назв. — англ. |
Репозитарії
Digital Library of Periodicals of National Academy of Sciences of Ukraine| _version_ | 1862736987662843904 |
|---|---|
| author | Galbiatti, A.L.S. Caldas, H.C. Padovani Junior, J.A. Pavarino, E.C. Goloni-Bertollo, E.M. |
| author_facet | Galbiatti, A.L.S. Caldas, H.C. Padovani Junior, J.A. Pavarino, E.C. Goloni-Bertollo, E.M. |
| citation_txt | Sensitivity of human laryngeal squamous cell carcinoma Hep-2 to metrotexate chemoterapy / A.L.S. Galbiatti, H.C. Caldas, J.A. Padovani Junior, E.C. Pavarino, E.M. Goloni-Bertollo // Experimental Oncology. — 2012. — Т. 34, № 4. — С. 367-369. — Бібліогр.: 22 назв. — англ. |
| collection | DSpace DC |
| container_title | Experimental Oncology |
| description | Aim: Methotrexate (MTX) is an antifolate agent that acts inhibiting purine and pyrimidine synthesis. The objective of the study was to evaluate the viability of Hep-2 human laryngeal cancer cells to the treatment with MTX chemotherapy in vitro. Methods: Cultured Hep-2 cells were treated with 0.25, 25.0 and 75 μM MTX for 24 h, and their viability was evaluated with Bcl-2-FITC antibody in flow cytometry. Results: The numbers of viable Hep-2 cells after 24 h treatment with 0.25, 25.0 and 75.0 uM MTX were 85.43%, 22.46% and 8.42%, respectively (p < 0.05). Therefore, MTX possesses a dose-dependent effect on viability of Hep-2 cells in vitro. Conclusion: The highest MTX concentration is associated with highest tumor cell sensitivity of human laryngeal cancer cells of Hep-2 line.
|
| first_indexed | 2025-12-07T19:56:35Z |
| format | Article |
| fulltext | |
| id | nasplib_isofts_kiev_ua-123456789-139856 |
| institution | Digital Library of Periodicals of National Academy of Sciences of Ukraine |
| issn | 1812-9269 |
| language | English |
| last_indexed | 2025-12-07T19:56:35Z |
| publishDate | 2012 |
| publisher | Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України |
| record_format | dspace |
| spelling | Galbiatti, A.L.S. Caldas, H.C. Padovani Junior, J.A. Pavarino, E.C. Goloni-Bertollo, E.M. 2018-06-21T12:37:44Z 2018-06-21T12:37:44Z 2012 Sensitivity of human laryngeal squamous cell carcinoma Hep-2 to metrotexate chemoterapy / A.L.S. Galbiatti, H.C. Caldas, J.A. Padovani Junior, E.C. Pavarino, E.M. Goloni-Bertollo // Experimental Oncology. — 2012. — Т. 34, № 4. — С. 367-369. — Бібліогр.: 22 назв. — англ. 1812-9269 https://nasplib.isofts.kiev.ua/handle/123456789/139856 Aim: Methotrexate (MTX) is an antifolate agent that acts inhibiting purine and pyrimidine synthesis. The objective of the study was to evaluate the viability of Hep-2 human laryngeal cancer cells to the treatment with MTX chemotherapy in vitro. Methods: Cultured Hep-2 cells were treated with 0.25, 25.0 and 75 μM MTX for 24 h, and their viability was evaluated with Bcl-2-FITC antibody in flow cytometry. Results: The numbers of viable Hep-2 cells after 24 h treatment with 0.25, 25.0 and 75.0 uM MTX were 85.43%, 22.46% and 8.42%, respectively (p < 0.05). Therefore, MTX possesses a dose-dependent effect on viability of Hep-2 cells in vitro. Conclusion: The highest MTX concentration is associated with highest tumor cell sensitivity of human laryngeal cancer cells of Hep-2 line. Fundação de Amparo а Pesquisa do Estado
 de Sгo Paulo (FAPESP) for their financial support
 (Nє 2010/12930-4, 2010/12932-7); Prof. Dr. Moacir F.
 Godoy for their help in statistical analysis; Profa. Dra
 Eloiza Helena Tajara for providing of the cell line; Oncology
 Department, Hospital de Base, São José do Rio
 Preto for providing of the Methotrexate Chemotherapeutic;
 CNPQ (National Counsel of Technological and
 Scientific Development) and FAMERP/FUNFARME. en Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України Experimental Oncology Short communications Sensitivity of human laryngeal squamous cell carcinoma Hep-2 to metrotexate chemoterapy Article published earlier |
| spellingShingle | Sensitivity of human laryngeal squamous cell carcinoma Hep-2 to metrotexate chemoterapy Galbiatti, A.L.S. Caldas, H.C. Padovani Junior, J.A. Pavarino, E.C. Goloni-Bertollo, E.M. Short communications |
| title | Sensitivity of human laryngeal squamous cell carcinoma Hep-2 to metrotexate chemoterapy |
| title_full | Sensitivity of human laryngeal squamous cell carcinoma Hep-2 to metrotexate chemoterapy |
| title_fullStr | Sensitivity of human laryngeal squamous cell carcinoma Hep-2 to metrotexate chemoterapy |
| title_full_unstemmed | Sensitivity of human laryngeal squamous cell carcinoma Hep-2 to metrotexate chemoterapy |
| title_short | Sensitivity of human laryngeal squamous cell carcinoma Hep-2 to metrotexate chemoterapy |
| title_sort | sensitivity of human laryngeal squamous cell carcinoma hep-2 to metrotexate chemoterapy |
| topic | Short communications |
| topic_facet | Short communications |
| url | https://nasplib.isofts.kiev.ua/handle/123456789/139856 |
| work_keys_str_mv | AT galbiattials sensitivityofhumanlaryngealsquamouscellcarcinomahep2tometrotexatechemoterapy AT caldashc sensitivityofhumanlaryngealsquamouscellcarcinomahep2tometrotexatechemoterapy AT padovanijuniorja sensitivityofhumanlaryngealsquamouscellcarcinomahep2tometrotexatechemoterapy AT pavarinoec sensitivityofhumanlaryngealsquamouscellcarcinomahep2tometrotexatechemoterapy AT golonibertolloem sensitivityofhumanlaryngealsquamouscellcarcinomahep2tometrotexatechemoterapy |